Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ADCT with free AI briefings, catalyst countdowns, and dilution alerts.

ADCT · ADC Therapeutics SA

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$219.1M Cash on Hand

31.7mo Cash Runway

5% Short Interest

$3.33 Analyst Target (3)

Follow ADCT by email Get an email when ADCT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADCT, unsubscribe in one click. Privacy

📣 What ADCT Says Is Next

Q2 2027 · “The Company also anticipates presentation of updated FL data in Q2 2027.”
Company press release, Aug 13, 2026 · SEC filing
the end of the year · “Updated MZL data were submitted to ASH and the Company anticipates presentation of this data before the end of the year, with publication and compendia submission to follow.”
Company press release, Aug 13, 2026 · SEC filing
this year · “The Company is also evaluating a regulatory pathway for this combination and plans to submit for Breakthrough Therapy designation (BTD) this year.”
Company press release, Aug 13, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Mar 2027 · Phase 1 · Active Trial · A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combi
Registry primary completion date, not a results date
Mar 2026 · Phase 3 · Active Trial · Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Parti
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Loncastuximab Tesirine (ADCT-402) FDA approved Apr 2021 · Zynlonta	B-cell Non Hodgkin Lymphoma	Phase 2/3 · NCT05991388	Recruiting
Odronextamab	B-cell Non Hodgkin Lymphoma	Phase 2/3 · NCT05991388	Recruiting
Chimeric Antigen Receptor T-cells	B-cell Non Hodgkin Lymphoma	Phase 2/3 · NCT05991388	Recruiting
Loncastuximab tesirine 75µg/Kg	Marginal Zone Lymphoma	Phase 2 · NCT05296070	Recruiting
Camidanlumab Tesirine (ADCT-301)	Acute Myeloid Leukemia (AML)	Phase 2 · NCT04639024	Terminated
Imvotamab	Non-Hodgkin Lymphoma	Phase 1/2 · NCT04082936	Terminated
Loncastuximab tesirine 150 µg/Kg	Marginal Zone Lymphoma	Phase 2 · NCT05296070	Recruiting
Idelalisib	Relapsed Follicular Lymphoma	Phase 2 · NCT04699461	Terminated
Vincristine	Double-Expressor Lymphoma	Phase 2 · NCT05600686	Active not recruiting
Doxorubicin	Double-Expressor Lymphoma	Phase 2 · NCT05600686	Active not recruiting
Epratuzumab-cys-tesirine (ADCT-602)	Blasts 5 Percent or More of Bone Marrow Nucleated	Phase 1/2 · NCT03698552	Terminated
Melphalan	Recurrent Diffuse Large B-Cell Lymphoma	Phase 1 · NCT05228249	Withdrawn
Trastuzumab/Tesirine Antibody-drug Conju	Breast Cancer	Phase 1 · NCT03125200	Terminated
Mipasetamab Uzoptirine (ADCT-601)	Advanced Solid Tumors	Phase 1 · NCT05389462	Terminated
Olintatug Tesirine (ADCT-901)	Advanced Solid Tumors	Phase 1 · NCT04972981	Completed

Also used in these trials (approved or third-party drugs, not ADCT's own candidates): Gemcitabine Hydrochloride, Rituximab, Etoposide Phosphate, Oxaliplatin, Carboplatin, Etoposide, Ifosfamide, Dexamethasone, Prednisone, Epcoritamab, Cyclophosphamide, Ibrutinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADCT holds $219.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $20.8M/quarter from operations, an estimated runway of 31.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Cash runway 32 months
Shelf registration (S-3, Aug 2024) +10
Share count +14% in a year +7

Recent financing filings on SEC EDGAR:

Feb 23, 2026 · Private placement (8-K Item 3.02) · 8-K
Oct 14, 2025 · Private placement (8-K Item 3.02) · 8-K
Jun 12, 2025 · Private placement (8-K Item 3.02) · 8-K
Aug 6, 2024 · Shelf registration, up to $300M · S-3
May 7, 2024 · Underwritten offering · 424B5
May 6, 2024 · Underwritten offering · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADCT files for a raise →

👥 Who Owns ADCT

Insiders 30.4% Other 5%+ holders 8.9% Institutions (150 holders) 60.7% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
Redmile Group, LLC 10% owner · +6.49M options	Insider	22,932,028	17.96%	2026-03-31
Nantahala Capital Management, LLC	Institution (13G, 5%+)	12,326,184	9.65%	2026-06-30
TCG Crossover GP II, LLC	5%+ holder (13G)	11,390,175	8.92%	2025-10-27
TCG Crossover Management, LLC	Institution (13F)	11,390,175	8.92%	2026-06-30
Hans Peter Wild 10% owner	Insider	9,788,944	7.67%	2025-05-15
Prosight Management, LP	Institution (13G, 5%+)	8,477,338	6.64%	2025-12-31
BlackRock, Inc.	Institution (13G, 5%+)	6,857,815	5.37%	2026-06-30
Point72 Asset Management, L.P.	Institution (13F)	3,649,144	2.86%	2026-06-30
Morgan Stanley	Institution (13F)	3,051,173	2.39%	2026-06-30
Millennium Management Llc	Institution (13F)	2,899,535	2.27%	2026-06-30
Ameet Mallik Chief Executive Officer, Director	Insider	2,121,769	1.66%	2026-06-30
Citadel Advisors Llc	Institution (13F)	2,053,316	1.61%	2026-06-30

Share count 127,667,695 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-06-30 filed 2026-07-02	MALLIK AMEET	Award (A)	675,000	–	2,121,769
2026-06-30 filed 2026-07-02	Zaki Mohamed	Award (A)	213,900	–	896,317
2026-06-30 filed 2026-07-02	GRAHAM PETER J	Award (A)	221,100	–	841,640
2026-06-30 filed 2026-07-02	Carmona Jose	Award (A)	203,700	–	938,076
2026-06-03 filed 2026-06-03	Monges Viviane	Tax withholding (F)	2,596	$3.08	186,447

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ADCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z